Navigate Fool.com
Will RCPT beat
the market?


Community Rating: 2 Stars: Unattractive

39.11 0.88 (2.30%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $37.92
Previous Close $38.23
Daily Range $37.37 - $39.12
52-Week Range $15.21 - $55.00
Market Cap $867.0M
P/E Ratio 173.77
Dividend (Yield) $0.00 (0.0%)
Volume 253,693
Average Daily Volume 514,784
Current FY EPS -$4.18

How do you think RCPT
will perform against the market?

Top RCPT Bull/Bear Pitches


zzlangerhans (< 20)
Submitted January 8, 2014

Receptos is a mid 2013 IPO that enjoyed a somewhat better reception than other IPO's from the class of 2013 that I have recently reviewed. Lead candidate RCP1063 is an S1P1 receptor modulator being de … More

0 Replies Reply Report this Post

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector

Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.

Sector Update: Healthcare

Sector Update: Healthcare Shares Flat Pre-Market

Up 37%: Can Receptos Compete With Novartis?

Receptos shareholders had a great day today -- how does the stock measure up in the multiple sclerosis industry?

Why Achillion Pharmaceuticals, Receptos, and Galena Biopharma Are Today's 3 Best Stocks

The S&P 500's winning streak comes to a subtle end as three biotech stocks roar higher.

Why Receptos Inc. Shares Exploded Higher

Receptos' shares take off following positive phase 2 data for its lead drug candidate. Find out what shareholders should really keep their eyes on.

Sector Update: Healthcare Stocks Higher in Late Trade; Receptos Rallies on Positive Results for Pros

Sector Update: Healthcare Stocks Higher in Late Trade; Receptos Rallies on Positive Results for Prospective MS Drug

Sector Update: Healthcare

Can Receptos' New Drug Beat Biogen?

Receptos shares are surging on positive midstage trial results for a multiple sclerosis treatment. Could Receptos challenge Teva and Biogen Idec in the indication one day?

Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon

Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.

See More RCPT News...




RECEPTOS INC Website: http://www.receptos.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks